WellCare, Centene reportedly interested in Aetna’s Medicare Advantage business

Aetna is looking to jettison its Medicare Advantage plans in order to placate antitrust concerns at the Department of Justice over its proposed merger with Humana, and Reuters is reporting at least two companies are competing for that portfolio.

Sources “familiar with the matter” say WellCare and Centene have submitted for bids for plans that cover around 350,000 patients, with a possible sale price of $1 billion.

To read more on the potential sale and how it may affect regulators’ final decision on the Aetna-Humana deal, click on the link below: 

Around the web

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Trimed Popup
Trimed Popup